N-PORT filing recap · July 2024
What did ARK Genomic Revolution ETF buy in July 2024?
Reported stock-position changes between this filing and the previous one. These are ARK Genomic Revolution ETF's own holdings, not the firm's.
Stock value
$1.45B
Positions
40
Estimated turnover
20.7%
Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.
Period in review
ARK Genomic Revolution ETF opened new positions in Tempus Ai and Senti Biosciences, then exited Senti Biosciences entirely. It trimmed Twist Bioscience, Caredx, Nurix Therapeutics, Moderna, Vertex Pharmaceuticals, and Veeva Systems, while adding to Intellia Therapeutics and Adaptive Biotechnologies. The fund substantially increased its stakes in 10x Genomics, Amgen, Absci, and Natera, and dramatically boosted Guardant Health. It also sharply reduced Exact Sciences, Incyte, Teladoc Health, and Ginkgo Bioworks.